UK’s first trade association for psychedelics launches
- PsyIndUK has been launched to promote collaboration and knowledge sharing in the psychedelics industry, while also representing the sector in policy and regulatory matters.
- The team leading PsyIndUK has extensive experience in scientific research, fundraising, organizational management, and political and regulatory engagement.
- The focus of PsyIndUK is on building the future of psychedelic medicine in the UK in a sustainable, evidence-based, and equitable manner, with a primary focus on psilocybin, LSD, mescaline, DMT, MDMA, and ketamine.
- Membership in PsyIndUK is open to companies and groups in the UK's psychedelics sector, offering benefits such as working groups, events, and advocacy opportunities.
PsyIndUK has launched to encourage collaboration and knowledge sharing across the psychedelics industry, as well as representing the sector with policymakers and regulators.
2024 has been a turbulent year for the development of psychedelic medicines, with some unexpected setbacks and overpromising. To counter this, a shared mission of PsyIndUK is to build the future of psychedelic medicine in the UK in a sustainable, evidence-based, and equitable way.
The team leading the trade association has decades of experience in undertaking scientific research, raising capital, running organisations, and political and regulatory engagement.
Led by psychedelics regulatory expert James Bunn, the PsyIndUK team also includes chair Dr Rayyan Zafar of Imperial College, and advisors Lucas McHugh and Mike Morgan-Giles.
Psychedelic Industry UK CEO James Bunn commented: “We’re proud to announce the launch of Psychedelic Industry UK. Now is the right time for this nascent industry to come together and collaborate to drive progress.
“Psychedelic Industry UK is delighted to welcome a range of leading players in the UK industry as founding members, with others expected to join in the coming period.”
PsyIndUK will take a holistic approach to psychedelic medicines, but will focus primarily on psilocybin, LSD, mescaline, DMT, MDMA, and ketamine.
Psychedelic Industry UK Chair Dr Rayyan Zafar added: “The psychedelic industry is expanding at a rapid pace, with notable progress with clinical trials and a growing recognition among the medical and wellness community.
“PsyIndUK is committed to rigorous scientific and medical research to guide therapeutic delivery, professional training for healthcare providers, and regulations to protect patient safety. We look forward to working across the sector to achieve this.”
The founding members of PsyIndUK are as follows:
Membership of PsyIndUK is open to companies and groups across the UK’s psychedelics space. Members will receive a range of benefits and services, including working groups, events, and advocacy. To find out more, please visit www.psyind.uk